Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
6 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Belite Bio, Inc’s names, not what it holds today.
Patents granted
6
6 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 2 in 2024 and none in 2023
Applications published
11
3 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Belite Bio, Inc its own name
named as the applicant on its applications, in US
11 publishedBelite Bio, Inc its own name
KY, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jul 22, 2025 | 12,364,693 | Methods of treating metabolic diseases with fused bicyclic pyrazoles | Pharmaceuticals | Belite Bio, Inc |
| Jun 25, 2024 | 12,016,853 | Methods of treating RBP4 related diseases with triazolopyridines | Pharmaceuticals | Belite Bio, Inc |
| Apr 9, 2024 | 11,951,100 | Formulations of RBP4 inhibitors and methods of use | Pharmaceuticals | Belite Bio, Inc |
| Jul 19, 2022 | 11,389,444 | Methods of treating metabolic diseases with fused bicyclic pyrazoles | Pharmaceuticals | Belite Bio, Inc |
| May 18, 2021 | 11,007,186 | Methods of treating RBP4 related diseases with triazolopyridines | Pharmaceuticals | Belite Bio, Inc |
| Apr 2, 2019 | 10,245,259 | Methods of treating RBP4 related diseases with triazolopyridines | Pharmaceuticals | Belite Bio, Inc |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Sep 25, 2025 | 2025/0295654 | METHODS OF TREATING METABOLIC DISEASES WITH FUSED BICYCLIC PYRAZOLES | Pharmaceuticals | Belite Bio, Inc |
| Jul 31, 2025 | 2025/0241902 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | Medical technology | Belite Bio, Inc |
| Feb 6, 2025 | 2025/0041227 | TABLET FORMULATIONS OF RBP4 INHIBITORS AND METHODS OF USE | Pharmaceuticals | Belite Bio, Inc |
| Dec 5, 2024 | 2024/0398780 | METHODS OF TREATING RBP4 RELATED DISEASES WITH TRIAZOLOPYRIDINES | Pharmaceuticals | Belite Bio, Inc |
| Jul 25, 2024 | 2024/0248099 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | Analysis of biological materials | Belite Bio, Inc |
| Dec 21, 2023 | 2023/0404984 | FORMULATIONS OF RBP4 INHIBITORS AND METHODS OF USE | Pharmaceuticals | Belite Bio, Inc · patent 11,951,100 granted from it |
| Dec 8, 2022 | 2022/0387400 | FORMULATIONS OF RBP4 INHIBITORS AND METHODS OF USE | Pharmaceuticals | Belite Bio, Inc |
| Nov 10, 2022 | 2022/0354844 | METHODS OF TREATING METABOLIC DISEASES WITH FUSED BICYCLIC PYRAZOLES | Pharmaceuticals | Belite Bio, Inc · patent 12,364,693 granted from it |
| Jul 29, 2021 | 2021/0228563 | METHODS OF TREATING RBP4 RELATED DISEASES WITH TRIAZOLOPYRIDINES | Pharmaceuticals | Belite Bio, Inc · patent 12,016,853 granted from it |
| Jun 25, 2020 | 2020/0197390 | METHODS OF TREATING METABOLIC DISEASES WITH FUSED BICYCLIC PYRAZOLES | Pharmaceuticals | Belite Bio, Inc · patent 11,389,444 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 3 · Analysis of biological materials 1 · Medical technology 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.